Get started
Work

155P A phase I study exploring the safety and tolerability of the small-molecule PD-L1 inhibitor INCB099280 in select advanced solid tumors

Year: 2023
Type: article
Study design: Clinical Trial
Abstract: INCB099280, an oral, programmed death ligand 1 (PD-L1) inhibitor, has shown preliminary efficacy and acceptable safety in an ongoing Phase 1, open-label, multicenter study in patients (pts) with advanced solid tumors (Prenen, et al. SITC 2022). Here we present updated results.
DOI: 10.1016/j.iotech.2023.100666
Authors: H. Prenen, T. Lesimple, M. Robert, J-P. Machiels, B.R. Delafontaine, P. Tomasini, T. Meniawy, N. Kotecki, E. Van Cutsem, S.A. Piha-Paul, M.T. Schweizer, S. Gadgeel, S. Kondo, K. Ouali, Y. Kuboki, J. Daniel, V. Ebiana, J. Howe, S. Spitz, A. Italiano
Institutions: Antwerp University Hospital, Centre Eugène Marquis, UniCancer Group, Cliniques Universitaires Saint-Luc, UCLouvain, Ghent University Hospital, Aix-Marseille Université, The University of Western Australia, Linear Clinical Research, Institut Jules Bordet, Universitair Ziekenhuis Leuven, KU Leuven, The University of Texas MD Anderson Cancer Center, University of Washington, Fred Hutch Cancer Center, Henry Ford Health, Henry Ford Hospital, National Cancer Center Hospital, Institut Gustave Roussy, Fondation Gustave Roussy, National Cancer Center Hospital East, Incyte (United States), Institut Bergonié
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,020
Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, Gilead Sciences, Celgene, F. Hoffmann-La Roche, BioMarin Pharmaceutical, Regeneron Pharmaceuticals, Merck KGaA, Les Laboratories Pierre Fabre, Mirati Therapeutics, BeiGene, Incyte, Calithera Biosciences, Aminex Therapeutics, Eisai, Astellas Pharma, Servier, PharmaMar, Ipsen, Sirtex Medical, Genentech, Chugai Pharmaceutical, Daiichi Sankyo Europe
OpenAlex ID: W4389480798
FWCI:
Cites:
Cited by:
Related to: 10